Market Intelligence, Clinical Progress, and High-Purity Reagents for Gastrointestinal and Cognitive Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HTR4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery (GPCR) | HTR4 Lentivirus Premade Particles. HEK293 expressed, high titer (>10^8 TU/mL), sequence verified, preserving native 7-TMD structure. For stable cell line construction (Calcium Flux/Flow Cytometry). | View HTR4 Products |
| Stable Cell Line Support | HTR4 Promise-ORF Clone. Full-length ORF with selectable markers for stable cell line construction. | View HTR4 Products |
| Antigen | HTR4 Membrane Prep / Nanodisc. High purity, preserving native multipass conformation. | View HTR4 Products |
| Benchmark Agonist | Anti-HTR4 (Prucalopride Reference). Positive control for binding assays. | View HTR4 Products |
| Validator | HTR4 siRNA Set (3 unique targets). For knockdown verification and target specificity screening. | View HTR4 Products |
| Off-Target Screen A | HTR3A (5-HT3 Receptor). Critical for selectivity assays (nausea liability avoidance). | View HTR3A Products |
| Off-Target Screen B | HTR2B (5-HT2B Receptor). Crucial counter-screening target for cardiovascular safety (valvulopathy risk). | View HTR2B Products |
| Off-Target Screen C | HTR2A (5-HT2A Receptor). Cardiovascular/CNS safety counter-screen. | View HTR2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Maintenance | Lentivirus-mediated stable cell expression preserves native 7-TMD structure and G-protein coupling. |
| Subfamily Off-Target Toxicity | Full panel of 5-HT receptor family lentiviruses (HTR1A, HTR2A, HTR2B, HTR3A) available for strict counter-screening. |
| Cross-species Preclinical Translation | Human/Mouse/Cyno HTR4 ortholog lentivirus available with sequence verified ORFs. |
| Functional Readouts | Optimized vectors for robust downstream cAMP and calcium mobilization assays. |
| False Positives | Sequence-verified siRNA included for rigorous specificity checks. |
Live HTR4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HTR4 therapeutics is diversifying and intensifying. Historically dominated by gastrointestinal applications (e.g., gastroparesis, IBS-C) with first-generation non-selective agonists like cisapride and tegaserod facing cardiovascular safety issues, recent R&D is heavily targeting cognitive and neurodegenerative disorders, particularly Alzheimer's disease, due to HTR4's role in promoting non-amyloidogenic cleavage of APP. The next wave of R&D is targeting extreme subtype selectivity and biased signaling ligands to completely bypass cardiovascular off-target risks while improving efficacy. Prucalopride has established the benchmark in GI motility, while emerging modalities include allosteric modulators and CNS-penetrant small molecules.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist (GI) | Takeda (Prucalopride), Theravance (Velusetrag), Johnson & Johnson | Chronic Constipation, IBS-C, Gastroparesis | cAMP Accumulation Assay (Need stable HTR4 over-expressing HEK293) |
| CNS-Penetrant Small Molecule | Various Biotechs | Alzheimer's Disease, Cognition | cAMP Accumulation & Selectivity Assay (Need full-length GPCR expression) |
| Allosteric Modulator | Early Biotech Pipeline | Alzheimer's Disease (Cognitive) | Binding Site Verification (Need orthosteric vs allosteric competition assays) |
| Peptide / Biologics | Emerging Innovators | Specialized GI Motility | Receptor Binding (Need structural preservation via cell-based assays) |
| SSRI Adjunct | Various | Depression (Combination) | HTR4 vs SLC6A4 selectivity panel |
Key Mutations & Functional Insights
- Diffuse leukoencephalopathy with spheroids mutation (UniProt VAR_067412): In a patient condition; uncertain significance.
- dbSNP rs34826744 (UniProt VAR_049364): Natural variant.
Note: These mutations are recorded but not directly impacting the drug discovery strategy outlined above.